CHMP Recommends Approval of BYETTA for Use With Basal Insulin

Amylin Pharmaceuticals, Inc.
AMLN
and Eli Lilly and Company
LLY
today announced that the Committee for Medicinal Products for Human Use (
CHMP
) of the European Medicines Agency (
EMA
) has issued a positive opinion in the European Union (
EU
) for the expanded use of BYETTA® (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos® (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. The CHMP's decision is now referred for final action to the European Commission, which has the authority to approve medicines for the EU. The Commission usually decides on CHMP recommendations within two to three months.
Loading...
Loading...
CHMP Logo
CHMPChampion Industries Inc
$0.00010-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
Not Available
Growth
Not Available
Quality
Not Available
Value
Not Available
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...